capecitabin fair-med 150 mg tabletti, kalvopäällysteinen
fair-med healthcare gmbh - capecitabinum - tabletti, kalvopäällysteinen - 150 mg - kapesitabiini
capecitabin fair-med 500 mg tabletti, kalvopäällysteinen
fair-med healthcare gmbh - capecitabinum - tabletti, kalvopäällysteinen - 500 mg - kapesitabiini
zoledronic acid fair-med 5 mg / 100 ml infuusioneste, liuos
fair-med healthcare gmbh - happo zoledronicum monohydricum - infuusioneste, liuos - 5 mg / 100 ml - tsoledronihappo
carbidopa/levodopa fair-med 12.5 mg / 50 mg tabletti
fair-med healthcare gmbh - levodopum,carbidopum monohydricum - tabletti - 12.5 mg / 50 mg - levodopa ja dekarboksylaasin estäjä
carbidopa/levodopa fair-med 25 mg / 100 mg tabletti
fair-med healthcare gmbh - levodopum,carbidopum monohydricum - tabletti - 25 mg / 100 mg - levodopa ja dekarboksylaasin estäjä
carbidopa/levodopa fairmed 25 mg / 250 mg tabletti
fairmed healthcare gmbh - carbidopa monohydrate, levodopa - tabletti - 25 mg / 250 mg - levodopa ja dekarboksylaasin estäjä
carbidopa/levodopa fairmed 25 mg / 100 mg tabletti
fairmed healthcare gmbh - carbidopa monohydrate, levodopa - tabletti - 25 mg / 100 mg - levodopa ja dekarboksylaasin estäjä
carbidopa/levodopa fairmed 12,5 mg / 50 mg tabletti
fairmed healthcare gmbh - carbidopa monohydrate, levodopa - tabletti - 12,5 mg / 50 mg - levodopa ja dekarboksylaasin estäjä
carbidopa/levodopa fairmed 10 mg / 100 mg tabletti
fairmed healthcare gmbh - carbidopa monohydrate, levodopa - tabletti - 10 mg / 100 mg - levodopa ja dekarboksylaasin estäjä
kauliv
strides pharma (cyprus) limited - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.